Therorna

Executive Summary

Therorna is a Suzhou-based Chinese biotech founded in 2019, specializing in RNA-based therapeutics and vaccines for infectious diseases. The company has developed proprietary delivery and modification technologies to enhance the stability and efficacy of its RNA constructs. Gaining prominence through its mRNA vaccine candidates during the COVID-19 pandemic, Therorna has since advanced its pipeline, with a lead candidate in Phase 3 trials. With a team of 200-500 employees, the company operates as a private entity and has yet to disclose total funding or valuation. Despite the competitive landscape, Therorna's focus on RNA platforms positions it well for addressing ongoing and emerging infectious disease threats. However, its reliance on the Chinese market and regulatory environment introduces specific risks associated with local approvals and market access.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 top-line data readout for lead mRNA vaccine candidate70% success
• Q4 2026Regulatory filing submission to NMPA for approval60% success